Press releases
- Antibe Announces Appointment of Receiver
- Antibe Provides Update on CCAA Proceedings
- Antibe Announces TSX Delisting Review
- Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
- Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
- Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
- Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
- Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
- Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
- Antibe Reports Q3 2024 Interim Financial and Operating Results
More ▼
Key statistics
On Tuesday, Antibe Therapeutics Inc(Pre-Merger) (ATBPF:PKC) closed at 0.2156, 93.71% above the 52 week low of 0.1113 set on Apr 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1889 |
---|---|
High | 0.2452 |
Low | 0.1889 |
Bid | -- |
Offer | -- |
Previous close | 0.2156 |
Average volume | -- |
---|---|
Shares outstanding | 53.01m |
Free float | 48.80m |
P/E (TTM) | -- |
Market cap | 15.64m CAD |
EPS (TTM) | -0.3466 CAD |
Data delayed at least 15 minutes, as of Apr 30 2024 12:30 BST.
More ▼